Recombinant IL21 (Avizakimab Biosimilar) antibody
Quick Overview for Recombinant IL21 (Avizakimab Biosimilar) antibody (ABIN7581498)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-IL-21 Reference Antibody (avizakimab)
-
Sequence
- QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYWMHWVRQA PGQGLEWMGT IDPSDQYTIY SQNFKGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARYG FAMDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL YITREPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK,DIQLTQSPSS LSASVGDRVT ITCRASQDIS NFLNWYQQKP GKAVKLLIYY TSRLHSGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCQQ GHTLPRTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
Characteristics
- Anti-IL-21 Reference Antibody (avizakimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: IL-21 inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- IL21 (Avizakimab Biosimilar)
-
Alternative Name
- IL-21 (Avizakimab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- Q9HBE4
Target
-